Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONRAD study of concomitant chemoradiotherapy for non-small cell lung cancer
ISRCTN63778716Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Nov 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Overall survival. Started Nov 2006; status: completed.
02
Drugs
vinorelbinecarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN63778716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63778716.